Skip to main content

Ashwagandha (Withaferin A) + Liposomal Doxorubicin

Combination Therapy for Recurrent Ovarian Cancer

  • RegistryNCT05610735
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionRecurrent Ovarian Cancer
  • SponsorSham Sunder Kakar
How Ashwagandha + Liposomal Doxorubicin worksNCT056107351 min

What the film says

Read the transcript

This trial is for adults with recurrent ovarian cancer for whom liposomal doxorubicin is a treatment option.

The idea: add ashwagandha, a plant extract containing withaferin A, taken as tablets by mouth, to the chemotherapy liposomal doxorubicin, given by vein every four weeks. The first part tests three ashwagandha doses.

This phase 1 and 2 study plans 72 patients and looks at feasibility, the maximum tolerated dose and progression free survival. At the University of Louisville's Brown Cancer Center, Whitney Goldsberry leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05610735

    Adults; recurrent ovarian cancer, liposomal doxorubicin acceptable; Ashwagandha tablets by mouth (withaferin A) with DOXIL IV every four weeks; First part tests three ashwagandha doses; Phase 1/2; 72 patients; feasibility, MTD, PFS (+1 more lines)

The drug

What is being tested.

Ashwagandha in the form of tablets will be administered orally on daily basis.

Administered orally on daily basis twice a day

Study Design Overview: This is a two-part open-label clinical trial of ASWD (Ashwagandha) administered to patients with recurrent ovarian cancer in combination with liposomal doxorubicin, (DOXIL) following at least one previous line of chemotherapy. Patients will initially be enrolled in part 1 of the study, which is the feasibility/tolerability evaluation. Once the part 1 enrollment is completed, the patients will be enrolled in part 2 of the study.

The study

How the trial runs.

The proposed study "combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in recurrent ovarian cancer" is focused to determine the feasibility and maximum tolerance dose of Ashwagandha with liposomal doxorubicin (DOXIL) in recurrent ovarian cancer patients. The study contains two parts.

In part 1 (phase I), 18 patients with recurrent ovarian cancer eligible for DOXIL therapy will be recruited and three doses of Ashwagandha (2.0 g, 4.0 g and 8.0 g) in the form of tablets along with DOXIL will be evaluated for feasibility and tolerance of ASWD.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Signed approved informed consent document stating that they understand the investigational nature of the treatment program before entering study
  • Female patients, age ≥ 18 years
  • Pathological confirmed ovarian, fallopian tube, or primary peritoneal carcinoma with the one of the following histologic types: high grade papillary serous carcinoma, low grade papillary serous carcinoma, high grade mucinous carcinoma, low grade mucinous carcinoma, clear cell carcinoma, high grade endometrioid carcinoma.
  • Received at least one line chemotherapy, which must be a platinum containing regimen and develop platinum resistance. Patients may have not received previous liposomal doxorubicin therapy, and must be considered to be eligible for single agent liposomal doxorubicin treatment.
  • Patients may have undergone surgical cytoreduction at the time of primary diagnosis or following neoadjuvant chemotherapy. Patients who had optimal (<1 cm residual disease) or suboptimal (>1 cm residual disease) following surgical cytoreduction will be included.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.